Status:

UNKNOWN

Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization

Lead Sponsor:

UMC Utrecht

Conditions:

Colorectal Neoplasms

Neoplasm Metastasis

Eligibility:

All Genders

18+ years

Phase:

PHASE2

PHASE3

Brief Summary

The objective of the SIM trial is to investigate whether using the Surefire Infusion System during holmium-166 radioembolization increases the posttreatment tumor to non-tumor activity concentration r...

Detailed Description

Study design: clinical within-subject randomized controlled trial. Study population: 25 patients with unresectable, chemorefractory, liver-dominant colorectal liver metastases. Intervention: scout a...

Eligibility Criteria

Inclusion

  • Written informed consent
  • Histopathologically confirmed diagnosis of adenocarcinoma of the colon or rectum
  • Hepatic metastases with measurable morphological appearance (≥ 1 cm) on cross sectional imaging, located in the right and left hepatic arterial perfusion territory
  • Unresectable, liver dominant disease
  • Progressive disease after second line chemotherapy or no further chemotherapeutical treatment options due to severe side effects or unwillingness of the patient to undergo systemic chemotherapy
  • Age ≥ 18 years
  • Expected adequacy of follow-up

Exclusion

  • World health organization performance score \> 2
  • Inadequate bone marrow function (hemoglobin \< 6.0 mmol/l, leukocyte count \< 3.0 x 109/l, platelet count \< 75x 109/l), inadequate liver function (bilirubin \> 35 µmol/l, aspartate aminotransferase / alanine aminotransferase (AST/ALT) \> 5 x upper limit of normal (ULN)) or inadequate renal function (creatinine \> 1.5 x ULN)
  • Prior hemihepatectomy
  • Compromised biliary system (biliary stent or hepaticojejunostomy)
  • Child Pugh score B7 or worse
  • Active hepatitis B or C
  • Main portal vein thrombosis on CT (or previous portal vein embolization)
  • Severe celiac axis stenosis on CT
  • Unsuitable hepatic arterial anatomy on CT
  • Treatment with systemic chemotherapy within 4 weeks prior to radioembolization
  • Previous participation in a study classified as class III by a radiation safety committee
  • Bleeding diathesis
  • Pregnancy or breast feeding
  • Life expectancy \< 3 months
  • Patients who are declared incompetent
  • Any condition that prevents from safe treatment with radioembolization

Key Trial Info

Start Date :

November 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

Estimated Enrollment :

25 Patients enrolled

Trial Details

Trial ID

NCT02208804

Start Date

November 1 2014

Last Update

November 9 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Radiology and Nuclear Medicine, University Medical Center Utrecht

Utrecht, Netherlands, 3584 CX